Bayer takes full control of Yakuhin
Germany's Bayer has taken over full control of its Japanesepharmaceutical affiliate, Bayer Yakuhin, as a result of terminating a joint venture agreement with Takeda Chemical Industries and Welfide Corp, reports Pharma Japan. Yakuhin's chairman, Knut Kleedehn, said that the change in status "is a key step in shaping up Bayer in Japan to pursue new business opportunities with full flexibility."
Acquisitions in the offing?
He went on to say that, with Yakuhin becoming a wholly-owned subsidiary, the firm is now "much better positioned to actively participate in the consolidation of the Japanese pharmaceutical industry." Mr Kleedehn added that "it is important for us to ensure taking the initiative for our company" when it wishes to merge with or acquire another firm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze